Efficacy of mirikizumab in resolving active histologic inflammation in ulcerative colitis in LUCENT-1 induction and LUCENT-2 maintenance trials

Key messages

• Absence of intra-epithelial neutrophils has been recommended as a minimum requirement for defining histological remission in ulcerative colitis (UC).
• Histologic and combined histologic/endoscopic endpoints were evaluated in UC patients who received mirikizumab through Week 52 in the LUCENT-1 trial.
• At Week 40, 54.8%, 48.5%, 47.7%, and 43.3% had achieved histologic improvement, histologic remission, histologic/endoscopic improvement and histologic/endoscopic remission with mirikizumab, compared to 25.7%, 24.6%, 22.3%, and 21.8% of induction responders re-randomized to placebo.
• Patients achieved resolution of active colonic inflammation with absence of neutrophils in the mucosa at induction, which was sustained or increased with continued mirikizumab.
• The incorporation of histologic and histologic/endoscopic outcomes as a potential treatment target could enhance the current treatment strategies in UC.